However, concomitant genetic alterations (such as CDKN2A copy number loss) [38] and the number of EGFR subclones [39] are associated with worse clinical outcomes in EGFR mutant NSCLC patients under TKIs treatment. Here, CDKN2A is linked to non-small cell lung carcinoma.